{"id":"hgp1408","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hot flashes"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Decreased libido"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Unlike traditional androgen receptor antagonists that block ligand binding, HGP1408 recruits the androgen receptor to the proteasome for degradation, resulting in complete loss of receptor function. This mechanism may overcome resistance mechanisms seen with conventional anti-androgens and provide more comprehensive suppression of androgen-driven signaling in hormone-sensitive cancers.","oneSentence":"HGP1408 is a selective androgen receptor degrader (SARD) that binds to and degrades the androgen receptor protein, eliminating both its transcriptional activity and protein expression.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:09.358Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Castration-resistant prostate cancer (CRPC)"},{"name":"Hormone-sensitive prostate cancer"}]},"trialDetails":[{"nctId":"NCT04324918","phase":"PHASE3","title":"Efficacy and Safety of HCP1102 Capsule in Patients With Perennial Allergic Rhinitis","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2018-10-23","conditions":"Perennial Allergic Rhinitis","enrollment":174},{"nctId":"NCT03371849","phase":"PHASE1","title":"PK and Safety Study of HCP1102, HGP0813 and HGP1408","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2017-07-19","conditions":"Healthy","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HGP1408","genericName":"HGP1408","companyName":"Hanmi Pharmaceutical Company Limited","companyId":"hanmi-pharmaceutical-company-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HGP1408 is a selective androgen receptor degrader (SARD) that binds to and degrades the androgen receptor protein, eliminating both its transcriptional activity and protein expression. Used for Castration-resistant prostate cancer (CRPC), Hormone-sensitive prostate cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}